Investors

 

Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer.

The company is listed on the regulated market of Euronext in Paris (access to Nanobiotix share price on our Euronext profile).

The company Headquarter is based in Paris, France, and has an affiliate in Cambridge (MA) United States.

 

IDENTIFICATION INFORMATION

Label NANOBIOTIX
Mnemonic NANO
ISIN Code FR0011341205
Bloomberg NANO:FP
Reuters NANO.PA
Issued Shares 22 360 039

NANOBIOTIX SHAREHOLDING STRUCTURE (DEC 2018)

  • Institutional Investors39%
  • Family Offices4%
  • Management & Employees6%
  • Retail51%

NANOBIOTIX ANALYST COVERAGE

STIFEL (UK) Christian Glennie
JEFFERIES (UK) Peter Welford
GILBERT DUPONT (FR) Jamila El Bougrini
KEMPEN (NL) Ingrid Gafanhao
KEPLER CHEUVREUX (FR) Arsène Guekam
H.C. WAINWRIGHT & Co. (US) Ramakanth Swayampakula
PORTZAMPARC (FR) Christophe Dombu
DEGROOF PETERCAM (BE) Benoit Louage
Note: The analysts listed above follow Nanobiotix. Any opinions, estimates or forecasts regarding Nanobiotix’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Nanobiotix or its management. Nanobiotix does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.
 

Download our latest
Corporate Presentation

 
English